Membrane-Coated Iron Oxide (Fe3O4) Nanoparticles Encapsulating Dacarbazine Suppress B16F10 Melanoma Cell Activity in vitro and in a Subcutaneous Mouse Model
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s635477 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Hao Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic & Cosmetic Surgery, Daping Hospital Army Medical University, Chongqing, 400042, People's Republic of China. Hauptthemen laut MEDLINE: Dacarbazine, Melanoma, Experimental, Magnetic Iron Oxide Nanoparticles, Magnetite Nanoparticles. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Malignant melanoma is a highly aggressive skin cancer. Dacarbazine (DTIC) chemotherapy, while historically used, is limited by poor solubility, short half-life, and systemic toxicity. Fe3O4 nanoparticles have been explored as drug delivery vectors with potential for photothermal conversion and Fenton-like catalytic activity. Cell membrane-camouflaged platforms may offer improved tumor targeting.
Methods
A biomimetic nanoplatform (Fe3O4PD@CCM) was engineered by encapsulating an Fe3O4 core within a DTIC-loaded PLGA-PEG2000 matrix, followed by functionalization with B16F10 cancer cell membranes. Physicochemical properties were characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), and liquid chromatography-mass spectrometry (LC-MS). Antitumor effects were assessed in B16F10 melanoma cells and in a subcutaneous syngeneic mouse model (n=4 per group).
Results
Fe3O4PD@CCM Nanoparticles (NPs) exhibited a hydrodynamic diameter of ~25-30 nm, sustained DTIC release, and retention of membrane proteins. In vitro, the Fe3O4PD@CCM + NIR (Near-infrared irradiation) group showed reduced cell viability, increased apoptosis, G2/M phase arrest, and elevated intracellular reactive oxygen species (ROS) levels compared to controls. In vivo, Cy5-labeled Fe3O4PD@CCM NPs showed preferential fluorescence accumulation in tumors relative to non-coated NPs, with whole-body fluorescence diminishing within 24 h. In a 12-day efficacy study, Fe3O4PD@CCM + NIR treatment was associated with reduced tumor growth compared to control groups. Acute biosafety assessment at 24 h post-injection of a single high dose (200 mg/kg) revealed no overt abnormalities in the evaluated hematological, biochemical, or histopathological parameters.
Conclusion
Fe3O4PD@CCM NPs combined with NIR suppressed B16F10 cell activity in vitro and subcutaneous tumor growth in a preliminary mouse model. These findings represent a proof-of-concept demonstration. Further studies-including detailed mechanistic validation, long-term toxicity assessment, and evaluation in more clinically relevant models-are required to assess the translational potential of this platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic & Cosmetic Surgery, Daping Hospital Army Medical University, Chongqing, 400042, People's Republic of China.
Zitieren
APA
Ding, H., Li, D. L., Zhou, Z. Y., Lai, X. D., Yang, N., Tan, L. C., & Lu, Y. G. (2026). Membrane-Coated Iron Oxide (Fe3O4) Nanoparticles Encapsulating Dacarbazine Suppress B16F10 Melanoma Cell Activity in vitro and in a Subcutaneous Mouse Model. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s635477
Vancouver
Ding H, Li DL, Zhou ZY, Lai XD, Yang N, Tan LC, et al. Membrane-Coated Iron Oxide (Fe3O4) Nanoparticles Encapsulating Dacarbazine Suppress B16F10 Melanoma Cell Activity in vitro and in a Subcutaneous Mouse Model. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s635477
BibTeX
@article{Ding2026,
author = {Ding, Hao and Li, Dan Li and Zhou, Zi Yi and Lai, Xiang Dong and Yang, Nan and Tan, Liu Chang and Lu, Yuan Gang},
title = {Membrane-Coated Iron Oxide (Fe3O4) Nanoparticles Encapsulating Dacarbazine Suppress B16F10 Melanoma Cell Activity in vitro and in a Subcutaneous Mouse Model},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s635477}
}
EUVIMED